FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry, in particular to a monoclonal antibody or its fragment, which specifically binds to Nav1.7. A pharmaceutical composition containing the specified antibody, polynucleotide encoding the specified antibody, and an expression vector containing the specified polynucleotide are also disclosed.
EFFECT: invention allows for the effective treatment of diseases associated with Nav1.7 factor.
9 cl, 5 dwg, 5 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| C3 BINDING AGENTS AND METHODS OF THEIR USE | 2019 |
|
RU2802307C2 |
| ANTI-SIRPα ANTIBODIES | 2018 |
|
RU2771174C2 |
| ANTI-CEACAM1 ANTIBODY AND ITS APPLICATION | 2018 |
|
RU2754876C2 |
| ADVANCED PROCOAGULANT ANTIBODIES | 2019 |
|
RU2810748C2 |
| MONOCLONAL ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT WHICH SPECIFICALLY BINDS TO 4Rα (GD2 GANGLIOSIDE) AND ITS USE | 2021 |
|
RU2808563C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2743464C2 |
| ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN AND METHODS OF THE USE THEREOF | 2015 |
|
RU2766094C2 |
| ANTIBODIES WHICH BIND TO SORTILIN AND INHIBIT THE BINDING OF PROGRANULIN | 2016 |
|
RU2735639C2 |
| ANTIBODIES DIRECTED AGAINST Fc-RECEPTOR-LIKE PROTEIN 5 AND METHODS FOR THEIR APPLICATION | 2016 |
|
RU2774158C2 |
| BISPECIFIC ANTIBODY | 2020 |
|
RU2814713C2 |
